Artikel
Expression difference of somatostatin receptors 1-5 in meningiomas
Expressionsunterschiede von Somatostatinrezeptoren 1-5 in Meningeomen
Suche in Medline nach
Autoren
-
Felix Behling
- Universitätsklinikum Tübingen, Klinik für Neurochirurgie, Tübingen, Deutschland
-
Christina-Katharina Fodi
- Universitätsklinikum Tübingen, Klinik für Neurochirurgie, Tübingen, Deutschland
-
Irina Gepfner-Tuma
- Universitätsklinikum Tübingen, Klinik für Neurochirurgie, Tübingen, Deutschland; Universitätsklinikum Tübingen, Klinik für Neurologie, Tübingen, Deutschland
-
Kathrin Machetanz
- Universitätsklinikum Tübingen, Klinik für Neurochirurgie, Tübingen, Deutschland
-
Marco Skardelly
- Universitätsklinikum Tübingen, Klinik für Neurochirurgie, Tübingen, Deutschland
-
Mirjam Renovanz
- Universitätsklinikum Tübingen, Klinik für Neurochirurgie, Tübingen, Deutschland
-
Kristina Kaltenbacher
- Universitätsklinikum Tübingen, Klinik für Neurologie, Tübingen, Deutschland
-
Christian La Fougere
- Universitätsklinikum Tübingen, Institut für Neuropathologie, Tübingen, Deutschland; Universitätsklinikum Tübingen, Nuklearmedizin und Klinische Molekulare Bildgebung, Tübingen, Deutschland
-
Jürgen Honegger
- Universitätsklinikum Tübingen, Klinik für Neurochirurgie, Tübingen, Deutschland
-
Ghazaleh Tabatabai
- Universitätsklinikum Tübingen, Klinik für Neurochirurgie, Tübingen, Deutschland; Universitätsklinikum Tübingen, Klinik für Neurologie, Tübingen, Deutschland
-
Marcos Tatagiba
- Universitätsklinikum Tübingen, Klinik für Neurochirurgie, Tübingen, Deutschland
-
Jens Schittenhelm
- Universitätsklinikum Tübingen, Institut für Neuropathologie, Tübingen, Deutschland
| Veröffentlicht: | 26. Juni 2020 |
|---|
Gliederung
Text
Objective: Beyond microsurgical resection and radiation therapy there are no established treatment alternatives for meningioma patients. In selected cases peptide radio receptor therapy (PRRT) can be implemented. In this study we analyzed the expression of somatostatin receptors 1, 2A, 3, 4 and 5 in meningiomas. Subgroup analysis has the potential to enable further refinement of this innovative treatment option.
Methods: Overall 786 meningiomas were operated in the authors’ institution between 01/2013 and 03/2017 of which562 tumor samples were processed into tissue microarrays and stained for SSTR1, 2A, 3, 4 and 5 immunohistochemically. Microscopic evaluation was done with a semiquantitative score regarding percentual quantification and staining intensity and results were correlated with clinical data.
Results: The analyzed cohort consisted of 399 female and 163 male patients (f/m-ration 2.4) with a mean age of 59.0 years (range 8.3 – 90.0 years). WHO grade I was diagnosed in 479 cases while 76 tumors were grade II and 7 grade III. Brain invasion was observed in 40 cases. There was a significant lower rate of SSTR3 and SSTR4 expression in meningiomas of male patients (p=0.0317 and 0.0216, respectively) but no significant correlation between patient age and SSTR expression. Significant expression differences were observed for SSTR3 and SSTR4 between WHO grades I through III with less expression in higher grades (p= 0.0005 and p=0.023, respectively). Similar results were observed for brain invasion with lower expression rates in meningiomas featuring invasive growth into central nervous system tissue (p=0.0275 and 0.0073, respectively). Expression of SSTR1 and 5 was highest in spinal meningiomas (p=0.0107 and p<.0001, respectively) while skull base meningiomas showed the highest expression for SSTR2A and 3 (p=0.0374 and p<.0001, respectively). No significant differences were observed for tumor location and SSTR4 expression.
Conclusion: Expression of SSTR3 and 4 is higher in WHO grade I tumors and female patients. Spinal meningiomas show higher expression levels of SSTR1 and 5 while SSTR2A and 3 are increased in skull base meningiomas. Currently used PRRT substances target SSTR2A. Marked differences of SSTR expressions between subgroups have the potential to select PRRT substances, depending on subtype expression for potentially more treatment efficacy.
